Search Within

Gabrielle Arauz

Formats
  1. Meeting Abstract (12)
  2. Journal Article (2)
Groups
  1. Advanced Practice Providers (14)
  2. Nursing (14)
  3. Department of Medicine (11)
  4. Genitourinary Oncology Service (11)
  5. Solid Tumor Oncology Division (11)
  6. Hematologic Malignancies, Division of (9)

More Groups

People
  1. Howard Scher (11)
  2. Susan Slovin (9)
  3. Michael Morris (7)
  4. Dana Rathkopf (6)
  5. Tracy Smart-Curley (6)
  6. Daniel Danila (5)

More People

Years
  1. 2020 (1)
  2. 2018 (1)
  3. 2017 (1)
  4. 2016 (1)
  5. 2015 (1)
  6. 2013 (2)

More Years

Publications
  1. Journal of Clinical Oncology (10)
  2. Oncology Nursing Forum (2)
  3. Cancer (1)
  4. Clinical Journal of Oncology Nursing (1)
Publishers
  1. American Society of Clinical Oncology (10)
  2. Oncology Nursing Society (ONS) (3)
  3. Wiley Blackwell (1)

Results (14)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Anderson, J.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Dayan, E. S.; Curley, T.; Arauz, G.; Baser, R. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study
    Meeting Abstract

    Rathkopf, D. E.; Autio, K. A.; Antonarakis, E. S.; Cheng, H. H.; Arauz, G.; Slack, A.; Hullings, M.; Scher, H. I.; Feng, F. Y.; Knudsen, K. E.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Halabi, S.; Carbone, E.; Fernandez, C.; Chen, Y.; Autio, K. A.; Rathkopf, D. E.; Kampel, L.; Morris, M. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Carbone, E.; Showunmi, A.; Hullings, M.; Morris, M. J.; Autio, K. A.; Kampel, L. J.; Molina, A. M.; Chen, Y.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment
    Journal Article

    Delacruz, A.; Arauz, G.; Curley, T.; Lindo, A.; Jensen, T.
    Clinical Journal of Oncology Nursing (2015)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Sadelain, M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Riviere, I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Shore, N.; Antonarakis, E. S.; Berry, W. R.; Alumkal, J. J.; Tutrone, R.; Saleh, M. N.; Redfern, C. H.; Hauke, R. J.; Liu, G.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Curley, T.; Rix, P. J.; Maneval, E. C.; Chen, I.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Rix, P. J.; Maneval, E. C.; Chen, I.; Fox, J. J.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save